Biocytogen Announces RenLite® Licensing Agreement with Janssen
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") (HKEX: 02315), today announced the signing of a non-exclusive license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (“Janssen”). Under the agreement, Biocytogen grants Janssen and its affiliates a non-exclusive worldwide license to use Biocytogen’s proprietary RenLite® platform and underlying intellectual property to discover, research, develop, manufacture and commercialize fully human antibody therapeutics with a common light chain and other biological therapeutics for an unlimited number of drug targets and indications. The agreement was facilitated by Johnson & Johnson Innovation LLC.
RenLite® is a member of Biocytogen's fully human antibody RenMice™ family. RenLite® mice can generate fully human antibody candidates with high specificity, affinity, diversity and good druggability, with a common light chain for subsequent assembly of bispecific and multispecific antibodies with a low mismatch and high success rate. The bispecific and multispecific antibodies assembled after RenLite® discovery have a traditional antibody structure and exhibit ideal physiochemical properties that are advantageous for downstream CMC development.
Dr. Yuelei Shen, Founder, Chairman and CEO of Biocytogen, said: “We are pleased to partner with Janssen to accelerate the discovery of new antibody-based drugs for patients.”
About RenMice™
RenMice™ are Biocytogen’s proprietary genetically modified mice that generate antibodies with fully human variable domains. The models, which include RenMab™, RenLite® and RenNano® mouse platforms, as well as substrains containing additional modifications, were developed using Biocytogen’s size-unlimited, precise chromosome engineering technology (SUPCE), which allows for in situ replacement of the murine immunoglobulin genes with their human counterpart. All RenMice platforms contain the entire human heavy chain VDJ loci, with the RenMab mouse harboring all human light chain VJ loci. In contrast, the RenLite mouse contains a single human VJ locus in situ to facilitate future bispecific antibody assembly, while the RenNano mouse has modified heavy chain constant regions to generate functional heavy-chain-only antibodies (HCAbs).
RenMice can generate robust immune response and produce fully human antibodies with great diversity, specificity, affinity and druggability. The development of RenMice has allowed Biocytogen to launch 6 fully human antibody discovery platforms: monoclonal antibody (RenMab), bispecific antibody and bispecific ADC (RenLite), nanobody (RenNano), TCR-mimic antibody for intracellular targets (HLA/RenMice, i.e., MHC humanized RenMice), and a RenMice HiTS (hyperimmune target specific) antibody platform designed for GPCR and other challenging targets.
As of June 30, 2022, RenMice have been licensed by 16 biopharmaceutical companies around the world, including Merck KGaA, Xencor, BeiGene, and Innovent.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMab™/RenLite®/RenNano® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, respectively, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. As of June 30, 2022, this project has resulted in 28 drug co-development agreements and 16 RenMice™ licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's internal pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230308005504/en/
Contact information
Biocytogen’s Contacts
Antibody platforms and antibody assets: BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Chef Marcus Samuelsson Invests in Aleph Farms, Plans to Serve Aleph Cuts Cultivated Steaks7.6.2023 16:14:00 EEST | Press release
Aleph Farms, a cellular agriculture company designing new ways to grow quality animal products, today announced that Chef Marcus Samuelsson is joining the company as an investor, culinary advisor and launch partner. Through much of his rise to fame as the celebrity chef behind 13 restaurants around the world, a New York Times best-selling author and a TV personality, Samuelsson has been using his unique background to elevate diversity in the culinary world. As part of this designation, he will work closely with Aleph Farms as it approaches commercialization of Aleph Cuts, the world’s first cultivated steaks, providing a new take on steak. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230607005267/en/ Marcus Samuelsson x Didier Toubia (Credit: Noi Einav) “Aleph Farms builds partnerships based on shared values. Like us, Chef Marcus believes in making a positive impact on our food systems with creativity, courage, and care,” s
Merz Therapeutics’ XEOMIN® (incobotulinumtoxinA) receives new therapeutic indication for the United Kingdom7.6.2023 16:09:00 EEST | Press release
Merz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins, received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK) for the use of XEOMIN® for the treatment of focal spasticity of the lower limb affecting the ankle joint. The approval, which previously included upper limb spasticity, has now been extended, enabling Merz Therapeutics to offer holistic support to people in the UK living with spasticity who require comprehensive treatment. “The label extension in the UK is an important step for Merz Therapeutics and the patients that we serve. With the UK becoming the second market, following Japan, to grant approval for the treatment of lower limb spasticity, affecting the ankle joint, it establishes the UK as the pioneering European country in this area. This approval supports our strong commitment to bringing better outcomes to more patients,” says Stefan König, CEO Merz Therapeutics. Enabling holist
Wipro and Cisco Launch Managed Private 5G-as-a-Service Solution to Accelerate Enterprise Digital Transformation7.6.2023 16:05:00 EEST | Press release
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading technology services and consulting company, today launched a managed private 5G-as-a-Service solution in partnership with Cisco (NASDAQ: CSCO). The new offering enables enterprise customers to achieve better business outcomes through the seamless integration of private 5G with their existing LAN/WAN/Cloud infrastructure. The changing nature of work and digital transformation across Information Technology (IT) and Operational Technology (OT) infrastructures are being driven by 5G and other complementary technologies. Managed private 5G from Cisco and Wipro supports organizations looking to enjoy the advantages of a private 5G network without having to acquire, run, and maintain one. The as-a-service solution benefits enterprise customers by minimizing the risks associated with upfront capital expenditure (Capex) investments and expedites technology adoption as Wipro and Cisco take on the technical, operational, and commercial
SoftServe Acquires Hoverstate7.6.2023 16:01:00 EEST | Press release
SoftServe, a global IT consulting firm, today announced its acquisition of Hoverstate, a full-service digital agency specializing in mobile and web-based solutions. The acquisition positions both companies as a single software solution source for digital native organizations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230607005221/en/ SoftServe, a global IT consulting firm, has announced acquiring Hoverstate, a full-service digital agency specializing in mobile and web-based solutions. (Graphic: Business Wire) SoftServe’s dynamic offerings and global footprint enhance Hoverstate’s intelligent process automation expertise and its key partnership with the Pega Platform from Pegasystems, the low-code platform provider empowering the world’s leading enterprises to Build for Change®. Clients now have deeper access to accelerated cloud-based digital processes and increased developmental efficiencies using data and analytics, A
Rimini Street’s Street Smart and Street Light Executive Series Strives to Bring Together Thousands of Global CXOs, IT and Finance Leaders into a Unique Community of Peer Learning, Networking and Sharing of Ideas7.6.2023 16:00:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, products and services, the leading third-party support provider for Oracle and SAP software, and a Salesforce and AWS partner, sees markedly increased participation in its Street Smart and Street Light executive series, with the most recent Street Smart event hosted in Tokyo, Japan in May 2023 bringing together nearly 200 influential CXOs and IT leaders into a single gathering. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230607005369/en/ Rimini Street’s Street Smart and Street Light executive series gain popularity with CXOs and IT leaders. (Photo: Business Wire) Attendees of the increasingly popular Rimini Street global events recognize and appreciate the exceptional quality of dialogue, new regional and industry connections and inclusion in an exclusive community of dynamic professionals eager to help one another navigate co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom